Growth hormone axis
Ipamorelin
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
The human evidence for Ipamorelin used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Ipamorelin at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 100–300 mcg per administration
- How often
- Every day
- Where
- Intravenous (clinical setting)
- Timing
- Often before bed and/or fasted, to line up with natural growth-hormone pulses; food with fat blunts the pulse in research.
- What people report
- Sleep and recovery contexts are commonly discussed within the first weeks.
- Time to steady level
- ~10 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- 8–12 weeks
- Break between
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C38H49N9O5
- Mol. weight
- 711.9 Da
- CAS
- 170851-70-4
- PubChem CID
- 9831659
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Ipamorelin describe 100–300 mcg per administration. Descriptive only, not a recommendation.
The human study was a single intravenous dose measuring pharmacokinetics; the multi-week subcutaneous schedules in circulation are community-derived, so no schedule table is shown.
What it can be combined with
How Ipamorelin is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- MK-677Both act on the ghrelin / growth-hormone-secretagogue pathway, so running them together stacks the same mechanism rather than adding a new one.Use caution
- CJC-1295 (DAC)GHRP plus a long-acting GHRH analog; the two axes combine rather than compete.Commonly combined
- CJC-1295 (no DAC)The classic pairing: a GHRP (ipamorelin) and a short GHRH analog amplify each other's growth-hormone pulse when co-timed.Commonly combined
- SermorelinGHRP plus a GHRH analog — different receptors, so they work together.Commonly combined
- TesamorelinGHRP plus a stabilised GHRH analog; complementary rather than redundant.Commonly combined
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GHRP / secretagogue pulsatility literatureGhrelin-mimetic GH release is pulsatile and synergises with GHRH analogs.